AUTHORS
Jennifer J Wilkes, MD MSCE, Aman Wadhwa, MD, MSPH2, Zachary Graff, MD3, Robert B. Gerbing, Ph.D4, Todd A. Alonzo, PhD5, Matthew A. Kutny, MD6, Lillian Sung, MD, PhD7, Alan S. Gamis, MD8, Richard Aplenc I, MD, PhD9, Jessica A. Pollard I, MD10, Brian Fisher, DO, MSCE11, Todd Cooper I, DO12
AFFILIATIONS
1 University of Washington School of Medicine, Seattle, Washington, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Children's Oncology Group, Arcadia, California, United States
5 Children's Oncology Group, Arcadia, California, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 The Hospital for Sick Children, Toronto, Ontario, Canada
8 University of Missouri-Kansas City, Kansas City, Missouri, United States
9 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Dana Farber Cancer Institute, Boston, Massachusetts, United States
11 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Washington School of Medicine, Seattle, Washington, United States
ABSTRACT
Infections due to immunosuppression from high-intensity chemotherapy are a significant cause of morbidity and mortality in children receiving treatment for acute myeloid leukemia (AML) attributed to prolonged periods of neutropenia and mucosal barrier disruption. These may lead to treatment delays, thereby compromising cure. During the past two decades, advances in supportive care practices such as antimicrobial prophylaxis and standardized central line management have occurred. However, the epidemiology of infections across this era among pediatric AML in the United States has not been previously reported. We address this gap in knowledge using data from patients enrolled on Children’s Oncology Group (COG) trials AAML0531 (2006-2011), AAML1031 (2011-2017) and AAML1831 (2020-present).
Patients with non-Down Syndrome newly diagnosed pediatric AML enrolled on these trials treated with cytotoxic chemotherapy alone were included in this secondary analysis. Patients with FLT3-ITD mutations were not included as enrollment of these patients is still ongoing on AAML1831. Enrolling sites reported sterile site infections for patients enrolled on the trials. Organisms reflecting microbiologically defined sterile site infections (on AAML0531 and AAML1031) and via Common Terminology Criteria for Adverse Events v5.0 for bacteremia, fungemia and sepsis episodes on AAML1831 were centrally adjudicated across each trial. Antimicrobial prophylaxis was not mandated across trials. Infectious events are reported as a proportion of patients with events of total patients receiving therapy in that cycle.
Across the three studies included, 2,966 patients were evaluated (AAML0531=1022 (34.5%), AAML1031=1226 (41.3%, and AAML1831=718 (24.2%). The median age at AML diagnosis was similar (AAML0531= 9.7, AAML1031=9.8, AAML1831= 10.0) across trials with age at study entry. White race represented 69.5% of patients over all three trials (2062/2966). Hispanic ethnicity was similar across AAML0531 (19.1%) and AAML1031 (17.9%), but slightly higher on AAML1831 (26.8%) for this evaluation.
Bacteremia events were more common across all studies than fungemia. Bacterial infections were prevalent during induction I over all three trials (AAML0531=194/1022, 19.0%, AAML1031=155/1226,12.6%, AAML1831= 69/718, 9.6%). The frequency of bacterial infections per patient was highest in intensification II among all three trials (AAML0531= 367/626, 58.6%, AAML1031=312/738, 42.3%; AAML1831= 123/349, 35.2%). Viridans group streptococci (VGS) remained the most common etiology of infection across all studies and cycles (n= 1297 events). Klebsiella spp.(n=291) and Escherichia coli (n=221) were the most common gram-negative bacteria.
Fungemia, while less common than bacterial infections, was also most common during Intensification II (AAML0531=3.2%, AAML1031=1.9% and AAML1831=1.1%).
Over the past two decades in COG pediatric AML clinical trials, infectious toxicities continue to be a critical complication during treatment. Reassuringly, the proportion of events in induction I and Intensification II have decreased. However, despite antibacterial prophylaxis being considered standard of care for patients with AML in the United States, VGS infections remain the most common etiology of infectious toxicity, especially during intensification II. An ongoing COG randomized trial is assessing the effectiveness of xylitol dental wipes in protecting against these oral commensals. Additionally, rates of fungemia remain low despite extended duration of neutropenia, likely because of routine antifungal prophylaxis during periods of neutropenia. Additional evaluations by chemotherapy regimens across trials and by individual risk factors for bacteremia are underway to inform whether these improvements are attributable to changes in supportive care or chemotherapy substitutions and will guide interventions towards prevention.
Acknowledgements: NCTN Operations Center Grant (U10CA180886) • NCTN Statistics & Data Center Grant (U10CA180899) • St. Baldrick’s Foundation • Jazz Pharmaceuticals provided financial funding for the study, and Astellas Pharma Inc. is a collaborator for the AAML 1831 study, including study funding and clinical supply.
DISCLOSURES
Jennifer J Wilkes, MD MSCE: No relevant conflicts of interest to declare.